Metastatic pancreatic cancer has one of the poorest prognoses in oncology, Hall says. Traditionally, the only treatment option for the majority of patients who present with metastatic disease is cytotoxic chemotherapy. This is particularly challenging because these regimens are difficult to tolerate for symptomatic patients. Watch here . . .
[/subhead]Michael J. Hall, MD, MS, chair, Department of Clinical Genetics, director, Gastrointestinal Risk Assessment, associate professor, Fox Chase Cancer Center, discusses the rationale for the POLO trial in metastatic pancreatic cancer.[/subhead]